PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

Description:
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

Summary

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Currently, treatment rates for HER2-positive breast cancer in China are low, with Roche reporting that approximately 30% of patients diagnosed with the disease actually received a treatment that contained an HER2-targeting therapy in 2013.

Scope

- An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the China HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
- Investigation of current and future market competition for HER2-Positive Breast Cancer.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

- Understand the trends shaping and driving the China HER2-Positive Breast Cancer market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the China HER2-Positive Breast Cancer market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in the China HER2-Positive Breast Cancer market landscape? Identify, understand and capitalize.
8.1 China
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers - Global Issues
8.1.4 China - Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed HER2-Positive Breast Cancer Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Global Head of Healthcare
9.8 About Us
9.9 Disclaimer

1.1 List of Tables
Table 1: AJCC Stage Definitions for Breast Cancer
Table 2: Prognosis for Breast Cancer in the US
Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
Table 4: Product Profile - Herceptin
Table 5: Clinical Studies for Herceptin in the Adjuvant Setting
Table 6: Herceptin SWOT Analysis, 2013
Table 7: Product Profile - Tykerb
Table 8: Tykerb SWOT Analysis, 2013
Table 9: Product Profile - Perjeta
Table 10: Perjeta SWOT Analysis, 2013
Table 11: Product Profile - Kadcyla
Table 12: Kadcyla SWOT Analysis, 2013
Table 13: Product Profile - Afinitor
Table 14: Afinitor SWOT Analysis, 2013
Table 15: Product Profile - Xeloda
Table 16: Xeloda SWOT Analysis, 2013
Table 17: Product Profile - Avastin
Table 18: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer
Table 19: Avastin SWOT Analysis, 2013
Table 20: Product Profile - Abraxane
Table 21: Abraxane SWOT Analysis, 2013
Table 22: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013
Table 23: Unmet Need and Opportunity in HER2-Positive Breast Cancer
Table 24: Product Profile - Gilotrif
Table 25: Gilotrif SWOT Analysis, 2014
Table 26: Product Profile - Neratinib
Table 27: Neratinib SWOT Analysis, 2013
Table 28: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014
Table 29: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2014
Table 30: Product Profile - Palbociclib
Table 31: Palbociclib SWOT Analysis, 2014
Table 32: Product Profile - NeuVax
Table 33: NeuVax SWOT Analysis, 2014
Table 34: Product Profile - Patritumab
Table 35: Patritumab SWOT Analysis, 2014
Table 36: Product Profile - Ganetesib
Table 37: Ganetesib SWOT Analysis, 2014
Table 38: Product Profile - ARRY-380
Table 39: ARRY-380 SWOT Analysis, 2014
Table 40: Product Profile - NVP-BYL719
Table 41: NVP-BYL719 SWOT Analysis, 2014
Table 42: Trastuzumab Biosimilars, 2014
Table 43: Sales Forecast ($m) for HER2-Positive Breast Cancer in China, 2013-2023
Table 44: Key Events Impacting Sales for HER2-Positive Breast Cancer in China, 2013-2023
Table 45: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 46: Chinese HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 47: HER2-Positive Breast Cancer Incidence, 2013-2023
Table 48: HER2-Positive Breast Cancer Drugs, Key Launch Dates
Table 49: HER2-Positive Breast Cancer Drugs, Key Patent Expiries
Table 50: Average Body Weight and Surface Area Across China Market
Table 51: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant
Table 52: Average Annual Cost of Therapy ($) - Perjeta, First Line
Table 53: Average Annual Cost of Therapy ($) - Tykerb, First Line
Table 54: Average Annual Cost of Therapy ($) - Kadcyla, Second Line
Table 55: Average Annual Cost of Therapy ($) - Halaven, Fourth Line
Table 56: Average Annual Cost of Therapy ($) - Abraxane, Fourth Line
Table 57: Average Annual Cost of therapy ($) - Ixempra, Fourth Line
Table 58: Average Annual Cost of Therapy ($) - Neratinib, Third Line
Table 59: Physicians Surveyed by Country

1.2 List of Figures
Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb
Figure 3: Active Late-Stage Clinical Trials for Perjeta
Figure 4: Active Phase III Clinical Trials for Kadcyla
Figure 5: Active Phase III Clinical Trials for Afinitor
Figure 6: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013
Figure 7: Gilotrif's Clinical Development in Breast Cancer
Figure 8: Clinical and Commercial Positioning of Gilotrif
Figure 9: Neratinib's Clinical Development
Figure 10: Clinical and Commercial Positioning of neratinib.
Figure 11: Sales for HER2-Positive Breast Cancer in China by Drug Class, 2013-2023

Ordering: Order Online - http://www.researchandmarkets.com/reports/3007019/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name: PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address: <a href="http://www.researchandmarkets.com/reports/3007019/">http://www.researchandmarkets.com/reports/3007019/</a></td>
</tr>
<tr>
<td>Office Code: SCBRECEB</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Product Format</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4995</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 9990</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 14985</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof] Last Name: ________________________________

First Name: ________________________________ Email Address: * ________________________________

Job Title: ________________________________ Organisation: ________________________________

Address: ________________________________ City: ________________________________

Postal / Zip Code: ________________________________ Country: ________________________________

Phone Number: ________________________________ Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World